Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Lineage Cell Therapeutics, Inc. reported revenue of $15M, up 53.2% year over year. Operating margin was -251.6% and net margin -436.5%, on a free-cash-flow margin of -133.6% with capital expenditure at 3.6% of revenue. Every figure is computed directly from LCTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $15M | -251.6% | -436.5% |
| FY2024 | $9M | -226.1% | -195.9% |
| FY2023 | $9M | -276.5% | -240.2% |
| FY2022 | $15M | -153.2% | -178.7% |
| FY2021 | $4M | -1133.6% | -991.0% |
How does LCTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.